{"entity":{"id":"nct06095505","kind":"trial","name":"A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of Alisertib in small-cell lung cancer, run by Puma Biotechnology, Inc., now recruiting.","summary":"A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer is a phase 2 interventional study registered as NCT06095505 by Puma Biotechnology, Inc., with 120 participants planned, started 2024-02-08 and due to reach its primary completion in 2027-10-30. Interventions recorded: Alisertib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06095505","url":"https://clinicaltrials.gov/study/NCT06095505"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["alisertib"],"companies":["puma-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06095505","phase":"2","setting":"A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer","sponsor":"Puma Biotechnology, Inc.","enrolled":120,"outcomes":[]},"route":"/trials/nct06095505/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"alisertib","kind":"drug","name":"Alisertib","route":"/drugs/alisertib/"}],"company":[{"id":"puma-biotechnology","kind":"company","name":"Puma Biotechnology","route":"/companies/puma-biotechnology/"}]}}